A Genetic Defect in Muscle Phosphofructokinase Deficiency, a Typical Clinical Entity Presenting Myogenic Hyperuricemia.
H NAKAJIMA,N KONO,T YAMASAKI,K HOTTA,M KAWACHI,T HAMAGUCHI,T NISHIMURA,I MINEO,M KUWAJIMA,T NOGUCHI,T TANAKA,S TARUI
DOI: https://doi.org/10.1007/978-1-4615-7703-4_32
1991-01-01
Abstract:The genetic defect in muscle phosphofructokinase deficiency (type VII glycogenosis, Tarui disease) was investigated. Six cDNAs for muscle phosphofructokinase, including a full-length clone, were isolated from a non-amplified library of muscle from a patient. By sequence analysis of these clones, a 75-base in-frame deletion was identified. The rest of the sequence was identical to that of the normal cDNA, except for a silent base transition at position 516 (ACT (Thr) to ACC (Thr)). The deletion was located in the 3’-terminal region of exon 13 (numbered with reference to the rabbit muscle phosphofructokinase gene (Lee, C.-P., Kao, M.-C., French, B. A., Putney, S. D., and Chang, S. Il. (1987) J. Biol Chem. 262, 4195-4199)). Genomic DNA of the patient was amplified by polymerase chain reaction. Sequence analysis of the amplified DNA revealed a point mutation from G to T at the 5’end of intron 13. This mutation changed the normal 5’-splice site of CAG:GTATGG to CAG:zTATGG. A cryptic splice site of ACT:GTGAGG located ‘75 bases upstream from the normal splice site was recognized and spliced in the patient.